Percutaneous Electrical Nerve Field Stimulator System for Functional Abdominal Pain Disorders (IB-Stim)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and coverage for the percutaneous electrical nerve field stimulator system (IB-Stim) as a treatment for pediatric functional abdominal pain disorders (including IBS) for Medicare Advantage and Commercial products.
Policy specifies age range, diagnostic requirements, prior therapy failures, contraindications, and CPT code 0720T for coverage of IB-Stim.
Coverage Criteria for IB-Stim (Percutaneous Electrical Nerve Field Stimulator)
Initial Therapy / Medical Necessity
Covered when ALL of the following are met:
Individuals with a history of a cardiac pacemaker, hemophilia, or psoriasis vulgaris are excluded from coverage for the percutaneous electrical nerve field stimulator system (IB-Stim).
Any use of the percutaneous electrical nerve field stimulator system (IB-Stim) that does not meet the specified medical necessity criteria (age, ROME IV diagnosis, exclusion of organic GI disease, minimum symptom duration, required prior medication trials, and absence of listed contraindications) is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.
Coding and Key Measures
| 0720T | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation |
Provider Actions, Authorization, and Denial Triggers
Prior Authorization Required
Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products. Verify member benefits and obtain prior authorization when applicable before initiating therapy.
- Applies to Medicare Advantage and Commercial products — benefits may vary by contract; check Benefit Booklet/Evidence of Coverage/Subscriber Agreement.
Required Prior Medication Trials
Patient must have tried and failed at least one medication in each of the following categories in addition to diet modification: acid suppression (H2‑blocker or PPI); antispasmodic or motility agent (e.g., hyoscyamine, dicyclomine, erythromycin/linaclotide, prucalopride); and a neuromodulator/antidepressant (e.g., amitriptyline, nortriptyline, gabapentin, periactin, aprepitant).
- Failure of medication trials must be documented in the medical record.
- Trials must include at least one agent from each of the three categories listed.
Prior Authorization and Benefit Verification
Verify member benefits prior to treatment. Prior authorization is required for Medicare Advantage and recommended for Commercial products; benefits and coverage criteria may vary by group/contract.
- Confirm coverage and medical necessity with the member's plan before scheduling therapy.
Denial Trigger — Failure to Meet Medical Criteria
Use of the percutaneous electrical nerve field stimulator (IB‑STIM) is considered not covered / not medically necessary when the patient does not meet ALL of the specified medical criteria (e.g., age 11–18, ROME IV functional GI diagnosis, organic GI disease ruled out, symptoms ≥9 months, required medication trial failures, and no contraindicated history such as cardiac pacemaker, hemophilia, or psoriasis vulgaris).
- If documentation does not demonstrate all required criteria, the request is subject to denial as not medically necessary/not covered.
- Denials may apply when required prior medication trials or duration of symptoms are not met.
Definitions and Device Description
Background and Clinical Context
Abdominal pain–related functional gastrointestinal disorders (FGIDs) are conditions in which pain is the predominant symptom without an identified organic cause, and they can substantially impair quality of life. Examples include irritable bowel syndrome (IBS), functional dyspepsia, abdominal migraine, functional abdominal pain, and functional abdominal pain syndrome. The IB-Stim is an auricular percutaneous electrical nerve field stimulation device intended to modulate central pain processing by delivering electrical impulses to cranial nerve branches in the external ear. Typical treatment courses reported in the clinical literature use applications over a 5-day period repeated across 3 consecutive weeks and randomized sham-controlled trials have shown reductions in worst abdominal pain and improvements in global symptoms and functioning.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.